Ecaterina Dumbrava, MD
Enriched profileAssociate Professor, Investigational Cancer Therapeutics, Cancer Medicine · The University of Texas MD Anderson Cancer Center
Ecaterina Dumbrava is Associate Professor, Investigational Cancer Therapeutics, Cancer Medicine at The University of Texas MD Anderson Cancer Center. OpenAlex indexes 394 publications with 2,688 citations (h-index 25); ClinicalTrials.gov lists 11 registered studies with this person as an investigator.
Data verified 27 Oct 2026
Overview
Updated 28 Oct 2026
Ecaterina Dumbrava, MD, is Associate Professor, Investigational Cancer Therapeutics, Cancer Medicine at The University of Texas MD Anderson Cancer Center. The public record shows 394 publications with 2,688 citations (h-index 25), centered on Cancer Immunotherapy and Biomarkers, Lung Cancer Treatments and Mutations, Immunotherapy and Immune Responses. It also documents an investigator role on 11 registered clinical trials, industry payments reported by 4 companies.
- Most recent indexed publication: 2026 · Journal for immunotherapy of cancer
- Top research focus: Cancer Immunotherapy and Biomarkers
- 11 registered trials on ClinicalTrials.gov
- Open Payments reporting from 4 companies
Generated from the cited public record · current as of 28 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 20 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 50.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 28 Oct 2026
Listed as an investigator on 11 registered studies on ClinicalTrials.gov. The most recent:
- A Study of TAK-505 in Adults With Solid Tumors
Sponsor: Takeda
- A Study of ZW251 in Participants With Advanced Solid Tumors
Sponsor: Zymeworks BC Inc.
- Phase I/Ib Trial of TIraGolumab, AtEzolizumab, and RadScopal Radiation in Patients With Advanced Solid Malignancies (TIGER)
Sponsor: M.D. Anderson Cancer Center
Industry payments
Updated 28 Oct 2026
4 companies reported payments to CMS in program years 2024–2025. These are public disclosures, not judgments. The latest:
- AstraZeneca UK LimitedProgram year20253 payments
- Genentech, Inc.Program year20252 payments
- Stemline Therapeutics Inc.Program year20251 payment
Medicare prescribing footprint (2022)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
57.1%Phenothiazine57.1%Prochlorperazine Maleate100%Part D≥14 patientsMetabolism & gastrointestinal
42.9%Serotonin-3 Receptor Antagonist42.9%Ondansetron Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 28 Oct 2026
135 congress contributions (2017–2026) across AACR, ASCO, ESMO per OpenAlex. The most recent:
- Abstract 2967: Evolution of TOP1 variants under selective pressure from topoisomerase-based therapeutics.
AACR Annual Meeting
AACR2026Co-author - Abstract 356: Rezatapopt and KRAS inhibitors for the treatment of TP53 Y220C and KRAS mutant cancers.
AACR Annual Meeting
AACR2026Co-author - Abstract LB429: Impact of severe liver metastases on clinical response to immunotherapy in solid tumors
AACR Annual Meeting
AACR2026Co-authorLate-breaking
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 28 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Phase 1/1b open-label, first-in-human study of HER2×CD3×CD28 trispecific T-cell engager (SAR443216) in participants with R/R HER2-expressing solid tumors.
Journal for immunotherapy of cancer
Clinical Trial2026 - Beamion PANTUMOR-1: rationale and design of a Phase II trial of zongertinib in HER2-overexpressed/amplified or HER2-mutant solid tumors.
Future oncology (London, England)
Article2026 - The actionable transcriptome: a framework for incorporating RNA sequencing into precision oncology.
Nature reviews. Clinical oncology
Review2026 - Advances in Targeting HER2 across Cancer Subtypes: A Pan-Tumor Approach.
Clinical cancer research
Review2026
Most-cited works
by citation count (OpenAlex)- 01
- 02
- 03Phase 2 study of pembrolizumab in patients with advanced rare cancersArticle133 citations2020
- 04
- 05
Network
Updated 28 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 28 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/ecaterina-dumbrava-md
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗
Mentions by others
where others cite or feature them- Other
faculty.mdanderson.org/profiles/ecaterina_ileanadumbrava.html
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →faculty.mdanderson.org ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 28 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- MD
University of Medicine and Pharmacy "Iuliu-Hatieganu", Cluj-Napoca, Romania (General Medicine)
verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗ - M.Sc.
Health Biology-Oncology/Early Drug Development, Paris South University, Orsay
verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
Editorial & leadership roles
journal and society appointments- Member of Editorial Review Board
Editorial Board of Journal of Immunotherapy and Precision Oncology (JIPO)
2023verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗ - verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
Awards & honors
honors on the public record- verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
Secondary affiliations
appointments beyond the home institution- Director
MD Anderson Molecular Tumor Board, The University of Texas MD Anderson Cancer Center
verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →orcid.org ↗ - Director for Investigational Cancer Therapeutics/Phase 1
The University of Texas MD Anderson Cancer Center
verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →orcid.org ↗ - Lead
ICT Inpatient Unit, The University of Texas MD Anderson Cancer Center
verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →orcid.org ↗ - Director
ICT Grand Rounds, The University of Texas MD Anderson Cancer Center
verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →orcid.org ↗ - ICT Serious Illness Conversation Guide (SICG) Trainer/ ACP Champion
The University of Texas MD Anderson Cancer Center
verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →orcid.org ↗ - Lead
ICT HER2 Working Group, The University of Texas MD Anderson Cancer Center
verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →orcid.org ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
- verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →faculty.mdanderson.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Hagop Kantarjian, MD
The University of Texas MD Anderson Cancer Center
Gabriel Hortobagyi, MD
The University of Texas MD Anderson Cancer Center
Jaffer Ajani, MD
The University of Texas MD Anderson Cancer Center
Funda Meric-Bernstam, MD
The University of Texas MD Anderson Cancer Center
Pasi Janne, MD, PhD
Dana-Farber Cancer Institute
Julie Brahmer, MD
Johns Hopkins University School of Medicine
Enriqueta Felip, MD, PhD
Vall d'Hebron Institute of Oncology (VHIO)
Funda Meric-Bernstam, MD
The University of Texas MD Anderson Cancer Center